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Executive Summary 
 
 
 
Substance identification 
The identification of 5F-MDMB-PICA (5F-MDMB-2201) (IUPAC name: methyl (2S)-2-{[1-(5-
fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate) has been described first in 
2016. Information obtained from seizures and collections suggests that it has been encountered in 
powdered form and as a synthetic constituent in herbal plant mixtures most commonly distributed 
for the purpose of smoking and/or vaping. It is the indole analogue of 5F-ADB (5F-MDMB-PINACA) 
that is listed in Schedule II of the Convention on Psychotropic Substances of 1971. 
 
WHO Review History 
5F-MDMB-PICA has not been previously pre-reviewed or critically reviewed. 
 
Chemistry 
There is no specific information available about the routes of synthesis employed for seized 5F-
MDMB-PICA products circulating on the drug market but straightforward methods for its 
preparation exist without requiring access to precursors that are controlled internationally. The 
presence of an asymmetric carbon atom gives rise to the (R)- and (S)-enantiomer and it seems 
likely for 5F-MDMB-PICA to be most commonly available as the (S)-enantiomer. 
 
Ease of convertibility into controlled substances 
There is no specific information available but it appears unlikely that 5F-MDMB-PICA is converted 
into a substance currently listed in any of the international drug conventions. 
 
Similarity to known substances / Effects on the central nervous system 
The information currently available suggests that 5F-MDMB-PICA functions as a synthetic 
cannabinoid receptor agonist (SCRA). Information about effects induced in vivo is currently not 
available but the existing data suggest that 5F-MDMB-PICA will likely exhibit a profile shared by 
other SCRAs controlled internationally (potent full agonists at cannabinoid receptors) such as 5F-
ADB. 
 
General pharmacology 
5F-MDMB-PICA, in its pure form but mostly as a synthetic constituent added to a plant matrix, is 
primarily smoked (or vaped) although reliable data about dosage are unavailable. A small number 
of in vitro studies are currently available and the data indicate that 5F-MDMB-PICA binds to and 
activates human CB1 and CB2 receptors at low nanomolar concentrations. 5F-MDMB-PICA acted as 
a full agonist at both receptor subtypes with significantly higher potency than Δ9-THC which has 
also been observed with other SCRAs that are listed in the Convention on Psychotropic Substances 
of 1971. Data collected from in vitro metabolism studies and detections in biological specimens 
revealed that the biotransformation observed included mono-hydroxylation, oxidative 
defluorination, dehydrogenation, amide, and ester hydrolysis, as well as combinations thereof. 
Glucuronidation products have also been detected.  
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Toxicology 
Information could not be identified. 
 
Adverse reactions in humans 
Detailed information about the clinical features associated with the consumption of 5F-MDMB-
PICA specifically is not available. However, “mass-overdose” cases were described in Connecticut 
(United States of America (USA)) that have been associated with the detection of 5F-MDMB-PICA 
and other SCRAs and fentanyl. Clinical features reported included decreased mental status, 
agitated delirium, and seizures. Within a 6-day period in September 2018, 244 overdose cases 
(details not reported) have been identified in Washington, DC, (USA) that also included the 
detection of 5F-ADB and other SCRAs. Data collected from intoxication cases with other SCRAs 
suggest that clinical features might include a range of adverse effects on gastrointestinal, 
neurological, and cardiovascular systems. 
 
Dependence potential 
No studies carried out in humans or animals could be identified. 
 
Abuse potential 
Studies specifically linked to 5F-MDMB-PICA could not be identified. 
 
Therapeutic applications / usefulness 
5F-MDMB-PICA is not known to have any therapeutic uses.  
 
Listing on WHO Model List of Essential Medicines 
5F-MDMB-PICA is not listed.  
 
Marketing authorizations 
5F-MDMB-PICA is not known to have any marketing authorisations. 
 
Industrial use 
5F-MDMB-PICA is not known to have any agricultural, industrial or cosmetic uses. 
 
Non-medical use 
The mode of use may involve the combinational use (intentionally or unintentionally) of other 
drugs and users may be unaware of the exact dose or compound being ingested (by whatever 
route). Household or subpopulation surveys that specifically probe for prevalence of 5F-MDMB-
PICA could not be identified. People who use SCRAs in general include recreational users, high-risk 
substance users but also individuals who are subject to drug testing such as people in drug 
treatment, prisoners, abstinence control programs and drivers.  
 
Nature and magnitude of public health problems 
Products sold as herbal smoking mixtures frequently change in drug composition and quantity, 
often without indications on product labels, which results in challenges to unambiguously 
correlate harms to public health with a specific drug such as 5F-MDMB-PICA. People who use 
these drugs are most likely not aware of the identity of the constituent and the quantity. The 
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consumption of these products might be attractive to a variety of users, such as regular users of 
cannabis and those who believe that SCRA use might help with avoiding a positive finding in drug-
testing procedures. There are indications that socially vulnerable and stigmatised substance users, 
for example found in homeless and prison populations, are increasingly associated with 
problematic use of SCRA products. Heavy use of SCRAs has been associated with problematic 
withdrawal symptoms and further research is needed to evaluate the underlying mechanisms. 
 
Licit production, consumption, and international trade 
5F-MDMB-PICA is available as standard reference material and produced for scientific research by 
a number of commercial suppliers. Other uses could not be identified. 
 
Illicit manufacture and traffic 
5F-MDMB-PICA began to emerge at the end 2016 both in Europe and the USA. In general, SCRAs 
are often imported in their pure form and converted into herbal forms on the domestic level. In 
recent years it has emerged that SCRAs have been smuggled into prisons in the form of 
impregnated papers (e.g. letters) and textiles and this extended to the detection of 5F-MDMB-
PICA. 
 
Current international controls and their impact 
5F-MDMB-PICA is not controlled under the 1961, 1971 or 1988 United Nations Conventions. 
 
Current and past national controls 
5F-MDMB-PICA is controlled in some UN Member States.  
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1.  Substance identification  
A. International Nonproprietary Name (INN) 
Not available. 
B. Chemical Abstract Service (CAS) Registry Number 
1971007-88-1 ((S)-enantiomer) 
C. Other Chemical Names 
Methyl (S)-2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate  
 
Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-
dimethylbutanoate 
 
N-[[1-(5-Fluoropentyl)-1H-indol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester 
 
D. Trade Names 
Not available. 
E. Street Names 
5F-MDMB-PICA  
5F-MDMB-2201 
5-Fluoro-MDMB-PICA 
5-Fluoro-MDMB-2201 
 
5F-MDMB-PICA has also been detected in a number of seized branded herbal 
smoking mixtures and product names included ‘Mind Trip’, ‘Devil’, ‘Armageddon’, 
‘Trippy Top’, ‘Tropical High’, ‘Astro’, ‘Red Russian’, ‘Supernova’, ‘AK-47’, ‘Dead Man 
Walking’, and ‘Joker’ (1). However, products associated with the sale of synthetic 
cannabinoid receptor agonists rarely retain the same composition and will 
frequently change over time. 
F. Physical Appearance 
5F-MDMB-PICA has been described as a white solid (2) and crystalline solid (3). 
G. WHO Review History 
5F-MDMB-PICA has not been previously pre-reviewed or critically reviewed. A 
direct critical review is proposed based on information brought to WHO’s attention 
that 5F-MDMB-PICA clandestinely manufactured, of especially serious risk to public 
health and society, and of no recognized therapeutic use by any party. Preliminary 
data collected from literature and different countries indicated that this substance 
may cause substantial harm and that it has no medical use. 
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2. Chemistry 
A. Chemical Name 
IUPAC Name: Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-
carbonyl]amino}-3,3-dimethylbutanoate  
 
Methyl N-[1-(5-fluoropentyl)-1H-indole-3-carbonyl]-3-methyl-L-valinate 
 
CA Index Name: L-Valine, N-[[1-(5-fluoropentyl)-1H-indol-3-yl]carbonyl]-3-
methyl-, methyl ester 
 
B. Chemical Structure 
Free base: 
 
Molecular Formula: C21H29FN2O3 
Molecular Weight: 376.47 g/mol 
  
C. Stereoisomers 
The presence of an asymmetric carbon atom gives rise to the (R)- and (S)-
enantiomer of 5F-MDMB-PICA. Historically, structurally related synthetic 
cannabinoid receptor agonists (SCRAs) that feature such chiral centres have 
typically shown the (S)-configuration. It is currently not known whether 5F-MDMB-
PICA has been exclusively found on the market with the absolute (S)-configuration 
although it appears very likely to be the case. Similar to other closely related SCRAs, 
it seems conceivable that the (R)-enantiomer might be detectable (e.g. 4, 5). 
D. Methods and Ease of Illicit Manufacturing 
Information on the manufacturing of 5F-MDMB-PICA seized or collected from the 
market is not available. Its preparation is straightforward and follows standard 
procedures using cheap reagents. One option used for the synthesis of 5F-MDMB-
O
O
NH
O
N
F
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PICA is shown in the Scheme below (2). Using a one-pot procedure, indole (A) was 
subjected to N-alkylation and conversion to the trifluoroacetylindole analogue (B). 
Hydrolysis gave the carboxylic acid intermediate (C) that then underwent coupling 
with L-tert-Leucine methyl ester to afford 5F-MDMB-PICA (D).  
 
 
 
 
Reagents and conditions: (a) (i) NaH, 1-bromo-5-fluoropentane, DMF, 0 °C−rt, 1 h; (ii) (CF3CO)2O, 
DMF, 0 °C−rt, 1 h; (b) 1 M aq. NaOH, MeOH, reflux, 24 h; (c) methyl L-tert-leucinate, EDC·HCl, HOBt, 
DIPEA, DMSO, rt, 24 h (2). 
  
E. Chemical Properties 
Melting point: 82−84 °C (2). 
 
Boiling point: Information could not be identified. 
 
Solubility: A sample obtained from a test purchase was reported to be soluble in 
dichloromethane and methanol and partially soluble in water (6). 
F. Identification and Analysis  
Data and analytical methodologies that facilitate the identification of 5F-MDMB-
PICA in various sample matrices are available and include physical characteristics 
(melting point), chromatographic, spectroscopic, and mass spectrometric methods 
(Annex 2).  
 
Analytical reference standards are accessible to assist with the implementation of 
routine methods of analysis associated with forensic and clinical investigations. The 
analytical determination of synthetic cannabinoid receptor agonists such as 5F-
MDMB-PICA in biological fluids can be a challenge, for example in cases where 
analytical methodologies are not specifically designed to detect these substances. 
In some instances (e.g. analysis of urine), the detection of metabolites may be the 
preferred approach. The explicit identification of the (S)-enantiomer has not been 
confirmed in the reports associated with the identification of 5F-MDMB-PICA but it 
appears conceivable that the 5F-MDMB-PICA available on the market 
predominantly exists as the (S)-enantiomer. However, until further information is 
available, one cannot exclude the existence of the (R)-enantiomer and the 
N
O
NH
O
O
N
H
N
O
CF3
N
O
OH
(a) (b) (c)
F F F
(A) (B) (C) (D)
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differentiation between the two might present challenges in routine forensic 
laboratories unless more specific approaches are employed to facilitate chiral 
analysis. The implementation of immunoassays for the analysis of human authentic 
urine samples containing 5F-MDMB-PICA metabolites was shown to be unreliable 
(1). 
3. Ease of Convertibility Into Controlled Substances 
No information could be identified.  
4. General Pharmacology 
A. Routes of administration and dosage 
5F-MDMB-PICA, in its pure form but mostly as a synthetic constituent added to a 
plant matrix, is primarily smoked (or vaped) although reliable data about dosage are 
unavailable. The variations in drug composition and quantities frequently observed 
with many smoking mixtures make such estimation impossible for users despite the 
information displayed on a product label (e.g. (7, 8)). It has been suggested that the 
amide and ester hydrolysis products might be expected to form during pyrolysis (1) 
though these might not retain psychoactive properties. Ten samples seized in New 
Zealand in 2017 were reported to contain 5F-MDMB-PICA with an average 
concentration of 9 g/kg (range 3–16 g/kg, RSD = 13%)) (9). 
B.  Pharmacokinetics 
Information from clinical studies in humans is not available. A recent study 
investigated the metabolic fate of 5F-MDMB-PICA in an in vitro assay using pooled 
human liver microsomes (1, 10). The identified phase I metabolites were then 
compared with metabolites obtained from authentic human urine samples (1). In 
this matrix, 12 phase I metabolites of 5F-MDMB-PICA were detected and assigned 
to 9 different biotransformations, including mono-hydroxylation, oxidative 
defluorination, dehydrogenation, amide, and ester hydrolysis, as well as 
combinations thereof. Eleven of the 12 metabolites were also detected in vitro. The 
four most abundant metabolites were 1) the methyl ester hydrolysis product, 2) the 
indole-N-propionic acid derivative, 3) a hydroxylated indole species, and 4) the 
hydroxylated (N-alkyl chain) methyl ester hydrolysis product. Numbers 1) and 3) 
were also considered suitable biomarkers for consumption of 5F-MDMB-PICA. Two 
of the main phase I metabolites were also identified as glucuronidation products 
(1).  
In a more recent investigation, 22 metabolites were detected following hepatocyte 
incubations and analysis of authentic human urine samples. Metabolites were 
formed via carboxylation or hydroxylation on the aliphatic chain or aromatic ring 
followed by glucuronidation; N-dealkylation followed by hydroxylation on the 
aromatic ring; oxidative defluorination followed by conversion to pentanoic acid; 
oxidative defluorination with conversion to propionic acid. Oxidative defluorination 
pathway also subsequently underwent hydroxylation on the aromatic ring followed 
by N-dealkylation or glucuronidation. The ester hydrolysis metabolite was further 
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metabolized via hydroxylation, glucuronidation, or dehydrogenation followed by N-
dealkylation, or ester hydrolysis with oxidative defluorination followed by 
dehydrogenation, or conversion to pentanoic acid. The two most abundant 
metabolites after the 5 h incubation with hepatocytes were ester hydrolysis and 
ester hydrolysis with oxidative defluorination (11). 
A. Pharmacodynamics 
Data currently available from some in vitro studies indicate that 5F-MDMB-PICA 
functions like a synthetic cannabinoid receptor agonist (SCRA) as it has been found 
to bind and activate CB1 and CB2 receptors (Table 1).  
 
Although the binding affinity ([3H]CP-55,940, HEK cells) was slightly lower (Ki = 5.4 
nM) compared to Δ9-THC (Ki = 2.5 nM) (12), the various functional assays employed 
revealed that 5F-MBMD-PICA was significantly more potent than Δ9-THC and other 
SCRAs used as positive controls. The available information also suggests that 5F-
MDMB-PICA is a potent agonist at both receptor subtypes (Table 1). At the time of 
writing, information on the in vivo effects of 5F-MDMB-PICA could not be identified.  
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Table 1. 5F-MDMB in-vitro data Reference 
 
Functional activity and efficacy: a 
 
5F-MDMB-PICA at hCB1: EC50 = 0.45 nM (Emax = 110%); hCB2: EC50 = 7.4 nM (Emax = 94%) 
Δ9-THC at hCB1: EC50 = 171 nM (Emax = 50%); hCB2: EC50 not determined; too low (Emax = 20% at 
10,000 nM) 
CP-55,490 at hCB1: EC50 = 42 nM (Emax = 100%); hCB2: EC50 = 68 nM (Emax = 100%) 
5F-ADB at hCB1: EC50 = 0.59 nM (Emax = 108%); hCB2: EC50 = 7.5 nM (Emax = 94%) 
 
(2) 
 
Receptor binding: b 
 
5F-MDMB-PICA at CB1: Ki = 5.4 nM 
(R)-(+)-WIN-55,212-2  at CB1: Ki = 21.4 nM 
Δ9-THC at hCB1: Ki = 2.46 nM 
 
Functional activity: c  
 
5F-MDMB-PICA, EC50 = 0.21 nM (Emax = 92.5%) 
(-)CP-55,940, EC50 = 0.53 nM (Emax = 102.3%) 
Δ9-THC, EC50 = 25.9 nM (Emax = 78.5%) 
 
(12) 
 
Functional activity and efficacy: d 
 
Operational efficacy tau at CB1: 5F-MDMB-PICA (314), CP-55,490 (91), WIN-55,212-2 (24),  Δ9-
THC (1.3). 
Functional affinity pKA  at CB1: 5F-MDMB-PICA (6.55), CP-55,490 (5.37), WIN-55,212-2 (5.27),  
Δ9-THC (5.65). 
Log (tau/KA): 5F-MDMB-PICA (9.12), CP-55,490 (7.53), WIN-55,212-2 (6.79),  Δ9-THC (6.18). 
 
(13) 
 
Functional activity and efficacy: e 
 
5F-MDMB-PICA at hCB1: EC50 = 3.26 nM (Emax = 331%); hCB2: EC50 = 0.87 nM (Emax = 244%) 
JWH-018 at hCB1: EC50 = 41 nM (Emax = 99.3%); hCB2: EC50 = 12.3 nM (Emax = 104%) 
 
(14) 
 
Functional activity (hCB1): f  
 
5F-MDMB-PICA, EC50 = 27.6 nM (Emax = 83%, 129%) 
5F-MDMB-PINACA (5F-ADB), EC50 = 15.7 nM (Emax = 88%, 136%) 
JWH-018, EC50 = 36.6 nM (Emax not reported, 100%) 
 
(11) 
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5. Toxicology 
Information could not be identified. 
 
6. Adverse Reactions in Humans 
Available reports associated with the detection of 5F-MDMB-PICA in biofluids are included 
in Appendix 2 though information about any clinical features associated with the detection 
of this drug (e.g. 1, 15), was not documented. The published information related to 
intoxications and adverse reactions are available in an aggregated form only which means 
that causal links with 5F-MDMB-PICA specifically cannot be identified based on the 
available information alone.   
 
“Mass-overdose” cases were described in New Haven, Connecticut (USA) that occurred in 
August 2018 where intoxicated patients presented to emergency departments (EDs) (16). 
Detailed information related to 5F-MDMB-PICA specifically was not reported. The 
information from the published abstract revealed the following: fifty-two patients 
presented over 109 ED visits (range 1–13 visits per patient); 49 of these visits occurred 
 
a Ref (2): murine AtT20-FlpIn neuroblastoma cells stably expressing human CB1 or CB2 receptors;  activation of 
CB receptors resulted in opening of endogenous G protein-gated inwardly rectifying potassium channels 
(GIRKs) that produced a hyperpolarisation of cells resulting in a decrease in fluorescence of a proprietary 
membrane potential dye. Comparison of test drugs was normalized against CP-55,940 response (set at 100% 
efficacy).  
 
b Ref (12): HEK cells; [3H]CP-55,940 (~1.3 nM) used as radioligand.  
 
c Ref (12): Adenylate cyclase assay using cyclic AMP ELISA kit. Basal cAMP subtracted from all values; CB1 
receptor agonists inhibit forskolin-stimulated cAMP formation with maximal inhibition defined using 1 µM  
(-)CP-55,940.   
 
d Ref (13): GIRK assay, see also a.  Irreversible CB1 antagonist AM6544 used to deplete 94% of receptor reserve 
followed by measurement of efficacy to generate CB1-dependent hyperpolarization in GIRK assay. tau 
parameter in the control state used to measure the CB1 agonist efficacy, representing the inverse of the 
number of receptors that need to be occupied by an agonist to produce a response 50% of the system 
maximum.  
 
e Ref (14): HEK cells;  assay based on NanoLuc Binary Technology via recruitment of β‐arrestin 2 (βarr2). 
Efficacy normalized to JWH-018 response.  
 
f Ref (11):  AequoScreen recombinant CHO-K1 cell lines (hCB1); digitonin used as a positive control for 
coelenterazine cell loading and blank wells with no drug used as negative controls. Activation was determined 
using a Tecan Spark™ microplate reader and compared to digitonin and JWH-018. 
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within a 10 h period on 15 August 2018. Symptoms described to vary significantly between 
visits (including patients with multiple visits) and included decreased mental status 
(51/109), agitated delirium (13/109), and seizures (5/109). Naloxone use was documented 
in 13/109 visits, with mixed responses. Two patients were intubated for decreased mental 
status. Urine samples from 21 patients were found to contain 5F-MDMB-PICA (5/21), 5F-
ADB and FUB-AMB metabolites (20/21), and fentanyl (4/21). Unstructured interviews with 
patients revealed that products containing SCRAs may have been given away freely or very 
cheaply by multiple dealers targeting methadone users in a competitive open-air market 
on the town green (16).  
 
The Background Information and Evaluation of ‘Three Factor Analysis’ (Factors 4, 5, and 6) 
for Temporary Scheduling document linked to the temporary placement of 5F-MDMB-PICA 
(among other SCRAs) into Schedule I of the United States Controlled Substances Act 
provided a summary of the number of exposure calls received by US poison control centres 
(Table 2). It has been stated that “the misuse of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-
AKB48, 5F-CUMYL-PINACA and FUB- 144 has been associated with law enforcement 
seizures, overdoses requiring emergency medical intervention, or both” but without 
providing further details (17). 
 
Table 2. Exposure cases of synthetic cannabinoids as reported to poison centres a,b,c 
Year Number of cases 
2011 6,968 
2012 5,230 
2013 2,668 
2014 3,682 
2015 7,797 
2016 2,706 
2017 1,959 
2018 (up to 30 September 2018) 1,627 
a Adapted from reference (17) 
 
 b American Association of Poison Control Centers (AAPCC), 23 October 2018 
 
c Summary of exposure calls related to SCRAs in general. 5F-MDMB-PICA identified in the 
USA first in October 2016 (17) and number of cases related to 5F-MDMB-PICA specifically, 
however, cannot be extracted from this table. 
 
The document announcing the temporary placement of 5F-MDMB-PICA (and 5F-EDMB-
PINACA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144) into Schedule I of the US Controlled 
Substances Act (18) also states that “In August 2018, in New Haven, Connecticut, in excess 
of 47 overdoses were reported following the use of a synthetic cannabinoid product. 
Analysis of drug evidence from the overdose event confirmed the presence of the 
synthetic cannabinoids 5F-ADB, FUB-AMB and 5F-MDMB-PICA” (see also above, reference 
(16) and Appendix 2). Furthermore, “from September 10 to 16, 2018, in Washington, DC, 
at least 244 overdoses were reported following use of a synthetic cannabinoid product. 
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Analysis of drug evidence from the overdose event confirmed the presence of the 
synthetic cannabinoids FUB-AMB and 5F-MDMB-PICA” (18). More specific information 
related to 5F-MDMB-PICA could not be identified.   
 
Reported adverse drug reactions associated with a range SCRAs frequently include 
gastrointestinal (e.g. nausea/hyperemesis), neurological (e.g. hallucination, agitation, 
anxiety, paranoia, confusion, delusions, catatonia, lethargy, psychosis (including 
susceptible individuals)), cardiovascular (e.g. tachycardia, hypertension) and renal (e.g. 
acute kidney failure) clinical features (e.g. (19-22)).   
 
In a recent UNODC communication to the ECDD secretariat, data from the UNODC’s 
ToxPortal that collects death and clinical cases contained 13 cases related to 5F-MDMB-
PICA (23). One incident was reported from the USA in 2018, one from Germany in 2018, 
and 10 from New Zealand 2018/2019. In 4 cases the contribution could not be determined, 
while it was rated low in 2, medium in 1 and high in another 6 cases. In an updated report 
provided by the UNODC that includes data obtained from the UNODC’s ToxPortal, a total 
number of 33 case reports involving the detection of 5F-MDMB-PICA were recorded (24). 
More detailed case level information was not provided (Table 3): 
 
Table 3. Toxicology reports according to data provided by the UNODC’s ToxPortal (24) 
Case 
reports 
Reporting country Type of cases Comments 
 
2017 (3) 
2018 (12) 
2019 (18) 
 
New Zealand (21) 
Singapore (8) 
Germany (2) 
USA (2) 
Post-mortem 
(17) 
15/17 poly-drug cases. 
NPS and controlled 
substances detected in 8 
cases and medicines in 3. 
Clinical 
admission (15) 
12/15 poly-drug cases. 
NPS and/or metabolites 
detected in 10 cases and 
controlled substances in 2 
cases. 
Other cases (1)  – 
 
5F-MDMB-PICA was detected in biological specimens collected from two post-mortem 
cases (11). In case 1, a 47-year-old male (history of drug abuse and diagnosed with type I 
diabetes) was found dead. Examination revealed pulmonary edema, fatty liver and 
underweight. Toxicological analysis showed no ethanol but 0.45 part per thousand of 
acetone in femoral blood as well as 0.60 part per thousand in urine. Vitreous glucose was 
78.4 mmol/L and the femoral blood had an elevated BHB at >1000 μg/g. The only 
exogenous compound found was 0.28 ng/g 5F-MDMB-PICA in femoral blood. The 
investigation concluded that the cause of death was diabetic ketoacidosis. In case 2, a 49-
year-old male (history of alcohol and drug abuse) was found dead. Examination was 
unremarkable without underlying pathology. The toxicological analysis revealed no ethanol 
but 0.13 part per thousand of acetone in femoral blood as well as 0.74 part per thousand 
in urine. Glucose was negative but the femoral blood had an elevated BHB at >1000 μg/g. 
42nd ECDD (2019):  5F-MDMB-PICA     
 
 
 
Page 18 of 30 
The only exogenous compound found was 0.32 ng 5F-MDMB-PICA/g femoral blood. The 
cause of death was considered due to ketoacidosis possibly with a contribution from drug 
use (11). 
7. Dependence Potential 
A. Animal Studies 
Information could not be identified. 
B. Human Studies 
Information could not be identified. 
 
8. Abuse Potential 
A. Animal Studies 
Information could not be identified. 
 
B. Human Studies 
Information could not be identified. 
 
9. Therapeutic Applications and Extent of Therapeutic Use and Epidemiology of 
Medical Use 
5F-MDMB-PICA is not known to have any therapeutic applications. 
10. Listing on the WHO Model List of Essential Medicines 
5F-MDMB-PICA is not listed on the WHO Model List of Essential Medicines. 
11. Marketing Authorizations (as a Medicinal Product) 
5F-MDMB-PICA is not marketed as a medicinal product 
12. Industrial Use 
5F-MDMB-PICA has no reported industrial use. 
 
13. Non-Medical Use, Abuse and Dependence 
Household or subpopulation surveys that specifically probe for prevalence of 5F-MDMB-
PICA could not be identified in the currently available literature. Epidemiological data, such 
as prevalence of use, abuse and dependence information, are not available specifically for 
5F-MDMB-PICA. The Monitoring the Future (MTF), a national cross-sectional survey in the 
United States of America that queries use of SCRAs among high-school attending 
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adolescents revealed a decrease in past-year use from 11.86% in 2011 to 4.75% in 2015. It 
was however found that the decrease was slower for some subgroups, predominantly 
those with high socioeconomic status and those who are frequent marijuana users. Across 
time, risk factors for use also include older adolescents, adolescents who identify as 
Hispanic/mixed race, and cigarette/other substance users (25). 
 
Heavy use of synthetic cannabinoid receptor agonists has been associated with 
problematic withdrawal symptoms (e.g. (26, 27)) and further research is needed to 
investigate the underlying mechanisms. As highlighted by the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA), people who use SCRAs include recreational users, 
high-risk drug users but also individuals who are subject to drug testing such as people in 
drug treatment, prisoners and drivers (28, 29).  
14. Nature and Magnitude of Public Health Problems Related to Misuse, Abuse and 
Dependence 
The majority of available SCRA products (including those containing 5F-MDMB-PICA) is sold 
in the form of herbal mixtures, and designed for smoking purposes and vaping (for example 
in the form of e-liquids). It is common for retailers to purchase bulk quantities of the 
synthetic substance and to add the synthetic material to a variety of vegetable matter as 
the plant base. Products sold as herbal smoking mixtures frequently change in drug 
composition and quantity, often without indications on product labels, which results in 
challenges to unambiguously correlate harms to public health with a specific drug such as 
5F-MDMB-PICA. The consumption of these products might be attractive to a variety of 
users, such as regular users of cannabis and those who believe that SCRA use might help 
with avoiding positive findings in drug-testing procedures. Ease of access, and perceived 
lack of legislative control might equally be of interest to some users. However, people who 
use these drugs are most likely not aware of the constituent and the quantity. The high 
potency associated with many SCRAs carries the risk of accidental overdose and potentially 
severe adverse events but information specific to 5F-MDMB-PICA is limited. Cases of 
impaired driving and motor vehicle collisions have been reported with closely related 
SCRAs such as the indazole analogue 5F-ADB (30). There are indications that socially 
vulnerable and stigmatised substance users, for example found in homeless and prison 
populations, are increasingly associated with problematic use of SCRA products (31-34). 
SCRA use in prisons has been associated with increase in aggression, violence, bullying and 
debt but also serious threats to safety and security of the prison environment (28, 29). The 
detections of 5F-MDMB-PICA in biological specimens (Section 16) confirm that this 
substance is consumed either intentionally or unintentionally though detailed information 
on the extent of use and circumstances is not available.  
 
A number of trend reports published in the USA have also featured the detection of 5F-
MDMB-PICA in various biological samples or sample extracts. In total, cases were 
submitted from 24 US States and the District of Colombia (Table 4).  
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Table 4. Trend reports that feature the detection of 5F-MDMB-PICA.a 
Time frame Positive findings 5F-ADB Reference 
Jan–Aug 2018 13 out of 1,037 specimens 
Metabolites: NRb 
Combinations: 6 
100 out of 1,037 specimens 
Metabolites: 61 
Combinations: 10 
(35) 
Oct–Dec 2018 27 out of 964 specimens 
Metabolites: 4 
Combinations: 8 
32 out of 964 specimens 
Metabolites: 31 
Combinations: 11 
(36) 
Jan–Mar 2019 52 out of 1,533 specimens 
Metabolites: 23 
Combinations: 13 
8 out of 1,533 specimens 
Metabolites: 19 
Combinations: 3 
(37) 
Apr–June 
2019 
64 out of 1,328 specimens 
Metabolites: 9 
Combinations: 10 
None reported. (38) 
a 5F-ADB (SCRA reviewed during 39th ECDD, (30)) results included for comparison. 
b NR: not reported. 
 
15. Licit Production, Consumption and International Trade 
5F-MDMB-PICA is available as standard reference material and produced for scientific 
research by a number of commercial suppliers. Other uses could not be identified. 
16. Illicit Manufacture and Traffic and Related Information 
EMCDDA received reports that 5F-MDMB-PICA (detection first notified in September 2016 
(39)) was encountered in seizures and collected specimens (herbal mixtures or powders) in 
Germany, Belgium, France, Denmark, Cyprus, Turkey, Sweden, Romania, Slovenia, 
Lithuania, Croatia, United Kingdom, and Serbia (40). SCRAs are typically imported from 
Chinese suppliers and prepared locally for distribution in their herbal form (28).   
 
5F-MDMB-PICA was first identified in the United States of America (USA) in October 2016 
(17).  
 
The National Forensic Laboratory Information System (NFLIS), which is dedicated to the 
collection of drug cases submitted by State and local laboratories in the USA, registered 
two reports in 2016, 84 in 2017, and 29 in 2018 (query date 25 July 2018) (17). At the same 
time of querying STRIDE and STARLiMS databases, no reports related to 5F-MDMB-PICA 
could be identified (17). The temporary scheduling order (USA, Controlled Substances Act) 
document stated that 5F-MDMB-PICA was identified in 381 NFLIS reports from 22 US 
States, since 2016 and 32 STRIDE/STARLiMS reports from seven US States and the District 
of Columbia, since 2017 (18). According to information received by the secretariat of the 
ECDD the total number of drug reports (NFLIS and federal forensic labs) (NFLIS data still 
pending for 2017-2018) was 849. In the period January 2018–June 2018, 197 reports 
related to 5F-MDMB-PICA were registered by NFLIS compared to 4,135 for 5F-ADB and 
2,972 for FUB-AMB (41).  
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Detections of 5F-MDMB-PICA have also been reported to UNODC’s Early Warning Advisory 
on New Psychoactive Substances (42). Detections of 5F-MDMB-PICA were reported by 6 
countries in 2016, 14 countries in 2017, and 10 countries in 2018 (as of 25 July 2019).  
 
UNODC’s evaluation of NPS emergence data (2015–2018) revealed the detection of 
5FMDMB-PICA in 20 countries: 7 reports in 2016, 14 reports in 2017, and 9 reports in 
2018, respectively (24). 
 
The US National DRUG Early Warning System (NDEWS) hosted at the University of 
Maryland (USA) publishes Emerging Threat Reports based on the US Drug Enforcement 
Administration’s Special Testing and Research Laboratory’s Emerging Trend Program. For 
the first quarter of 2019, the report featured 9 out of 30 identifications (43).  
 
In recent years it has emerged that SCRAs have been smuggled into prisons in the form of 
impregnated papers (e.g. letters) and textiles (29, 44, 45) including 5F-MDMB-PICA (46).  
 
In a drug-monitoring pilot programme covering three Scottish prisons in the United 
Kingdom, suspected SCRA-infused paper samples were seized for analytical evaluation in 
the period between 01 June 2018 and 01 July 2019. In this period, 257 individual paper 
samples obtained from 116 seizures were analysed which revealed the detection of at least 
one SCRA in 108 samples (42%). 5F-MDMB-PICA began to emerge in November 2018 and 
became one of the most commonly detected SCRAs (36.7%, n = 106 in total), thereby 
replacing 5F-ADB, and FUB-AMB as the most commonly detected compounds in infused 
papers until that time (47). 
17. Current International Controls and Their Impact 
5F-MDMB-PICA is not controlled under the 1961 (as amended by the 1972 Protocol), 1971 
or 1988 United Nation Conventions. 
18. Current and Past National Controls 
Refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
19. Other Medical and Scientific Matters Relevant for a Recommendation on the 
Scheduling of the Substance 
No further comments. 
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Annex 1: Report on WHO Questionnaire for Review of Psychoactive 
Substances  
 
Refer to separate Annex 1: Report on WHO questionnaire for review of psychoactive substances 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42nd ECDD (2019):  5F-MDMB-PICA     
 
 
 
Page 28 of 30 
 
Annex 2: Investigations associated with the chemical analysis of 5F-MDMB-
PICA (amongst other substances) including those reported in the published 
scientific literature 
 
 
 
Techniques a,b Comment Reference 
MP, TLC, NMR, ESI-MS, IR Analysis of synthesised sample for pharmacological testing (1) 
GC-MS Analysis of reference material (2) 
IR, GC, EI-MS, NMR Analysis of seized sample (3) 
EI-MS, IR, ESI-MS, IC Analysis of collected sample (4) 
GC-MS, LC-PDA, LC-MS, 
ESI-MS, NMR  
Analysis of seized sample (5) 
NR Analysis of seized samples (6) 
GC-MS, LC-MS, NMR Analysis of seized samples and biological specimens (7, 8) 
GC-MS, LC-MS, IM Analysis of seized samples, biological specimens and 
metabolism study 
(9) 
LC-MS Analysis of hair samples (10) 
LC-MS Elucidation of structure-metabolism relationships using pooled 
human liver microsomes 
(11) 
LC-MS Analysis of biological specimens and seized samples (12) 
LC-MS Analysis of biological specimens  (13) 
LC-MS, FC, NMR Analysis of seized MDMB‐CHMICAc samples and identification 
of 5F-MDMB-PICA as a contaminant  
(14) 
IM, LC-MS Analysis of biological specimens related to “mass overdose” 
cases. 
(15) 
Raman Analysis of seized/collected samples (16) 
IR, GC-MS, GC-FID Analysis of seized samples in New Zealand in 2017 (17) 
LC-MS In vitro metabolism assay and analysis of biological specimens (18) 
LC-MS Analysis of biological specimens (19) 
LC-MS Analysis of biological specimens, identification metabolites and 
in vitro hCB1 receptor activation  
(20) 
a As of July 2019. 
 
b MP: melting point; TLC: thin-layer chromatography; NMR: nuclear magnetic resonance spectroscopy; ESI: 
electrospray ionisation; MS: mass spectrometry (may involve high or low resolution approaches); IR: infrared 
spectroscopy; GC: gas chromatography; EI: electron ionisation; IC: ion chromatography; LC: liquid 
chromatography (various forms); PDA: photo diode array detection; FC: flash chromatography; IM: 
immunoanalysis; NR: details not reported; FID: flame ionisation detection.  
 
c MDMB‐CHMICA: methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate, a 
synthetic cannabinoid receptor agonist. 
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